Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients

Atherosclerosis

Volumn 123, Issue 1-2, 1996, Pages 193-202

  Bostom, Andrew G ^a   Shemin, Douglas ^b   Lapane, Kate L ^c   Nadeau, Marie R ^a   Sutherland, Patrice ^d   Chan, Jennifer ^e   Rozen, Rima ^e   Yoburn, David ^b   Jacques, Paul F ^a   Selhub, Jacob ^a   Rosenberg, Irwin H ^a  

^a TUFTS UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d Framingham Study   (United States)

^e RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Arteriosclerosis; B vitamin status; End stage renal disease; Genetics; Homocysteine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; PYRIDOXAL 5 PHOSPHATE; VITAMIN B GROUP;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIALYSIS; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029885203     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05809-1     Document Type: Article

References (41)

1. Parfrey PS, and Harnett JD. Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephr 1994;23:311.
2. Churchill DN. Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients. Kidney Int 1993;43(Suppl. 40):S16.
3. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kid Dis 1992;19:505.
4. Ueland PE, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989;114:473.
5. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693.
6. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975;24:721.
7. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633.
8. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59.
9. Guttormsen AB, Svarstad E, Ueland PM, Refsum H. Elimination of homocysteine from plasma in subjects with endstage renal failure. Irish J Med Sci 1995;164(suppl. 15):8 (abstract).
10. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301.
11. Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine mixed disulfide in patients on maintenance haemodialysis. Clin Sci 1980;58:427.
12. Kang SS, Wong PWK, Bidani A, Milanez S. Plasma protein-bound homocyst(e)ine in patients requiring chronic hemodialysis. Clin Sci 1983;65:335.
13. Smolin LA, Laidlaw SA, Kopple JD. Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987;45:737.
14. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocyst(e)inemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993;43(Suppl 41):S72.
15. Hultberg B, Andersson, Sterner G. Plasma homocysteine in renal failure. Clin Nephr 1993;40:230.
16. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404.
17. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995;47:247.
18. Kim SS, Hirose S, Tamura H et al. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients. Adv Perit Dial 1994;10:282.
19. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93.
20. Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995;6:121.
21. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1995;274:1049.
22. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995;10:111.
23. Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenete-trahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7.
24. Bostom AG, Shemin D, Lapane KL et al. Excess prevalence of hyperhomocysteinemia in dialysis dependent end-stage renal disease. Irish J Med Sci 1995;164(supplement 15):3 (abstract).
25. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1.
26. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-magnesium precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982;28:1379.
27. Owen WF, Lew NL, Liu SM, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentrations as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001.
28. Nolph KD, Moore HL, Twardowski ZJ et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J 1992;38:M139.
29. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43.
30. Shin-Buering Y, Rasshofer R, Endres WA. A new enzymatic method for pyridoxal 5″-phosphate determination. J Inherit Metab Dis 1981;4:123.
31. Horne DW, Patterson D. Lactobacillus casei assay of folic acid derivatives in 96-well microtiter plates. Clin Chem 1988;34:2357.
32. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015.
33. SAS Version 6.08, SAS Institute Inc., Cary, N.C., 1990.
34. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215.
35. Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147.
36. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475.
37. Cressman MD, Abood D, O'Neil J, Hoff HF. Lp(a) and premature mortality during chronic hemodialysis treatment. Chem Phys Lipids 1994;67/68:419.
38. Excerpts From The United States Renal Data System, United States Renal Data System 1995 Annual Report. Am J Kid Dis 1995;26(suppl. 2):S1.
39. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. In: Kannel WB, Wolf PA, Garrison RJ. (eds). The Framingham Heart Study: an epidemiological investigation of cardiovascular disease, section 34. Bethesda, MD: National Heart, Lung, and Blood Institute (1987) National Institutes of Health publication no. 87-2703.
40. Ahmed WH, Pashos CL, Ayanian AZ, Bittl JA. 30-day and 1-year mortality in hemodialysis patients undergoing coronary revascularization: results from a national cohort. Circulation 1995;92:I-75 (abstract).
41. CANADA-USA (CANUSA) multicenter study of peritoneal dialysis adequacy: description of the study population and preliminary results. CANUSA Peritoneal Dilaysis Study Group. Adv Perit Dial 1992;8:88.